Sputnik-V".Addressing the editor of The Lancet, the international peer-reviewed medical journal in which Moscow's Gamaleya Institute published its early-stage trial results, the scientists said they saw patterns in the data that looked "highly unlikely".The letter, published on the personal blog page of one of the signatories, said the Phase I/II trial results data showed multiple participants reporting identical antibody levels."On the ground of simple probabilistic evaluations the fact of observing so many data points preserved among different experiments is highly unlikely," the open letter said.However, the scientists said they were basing their conclusions on summaries of the Russian trial result data, published in the journal, rather.